questionsmedicales.fr
Métabolisme
Métabolisme glucidique
Glycosylation
Glycosylation : Questions médicales fréquentes
Termes MeSH sélectionnés :
Programmed Cell Death 1 Receptor
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Glycosylation : Questions médicales les plus fréquentes",
"headline": "Glycosylation : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Glycosylation : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-05-04",
"dateModified": "2025-04-29",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Glycosylation"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Métabolisme glucidique",
"url": "https://questionsmedicales.fr/mesh/D050260",
"about": {
"@type": "MedicalCondition",
"name": "Métabolisme glucidique",
"code": {
"@type": "MedicalCode",
"code": "D050260",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "G03.191"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Glycosylation",
"alternateName": "Glycosylation",
"code": {
"@type": "MedicalCode",
"code": "D006031",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Christian Marcus Pedersen",
"url": "https://questionsmedicales.fr/author/Christian%20Marcus%20Pedersen",
"affiliation": {
"@type": "Organization",
"name": "Department of Chemistry, University of Copenhagen, Universitetsparken 5, 2100 Copenhagen Ø, Denmark."
}
},
{
"@type": "Person",
"name": "Yanjing Li",
"url": "https://questionsmedicales.fr/author/Yanjing%20Li",
"affiliation": {
"@type": "Organization",
"name": "Department of Emergency, State Key Laboratory of Biotherapy, West China Hospital, and School of Chemical Engineering, Sichuan University, No. 17 Renmin Nan Road, Chengdu, 610041, China."
}
},
{
"@type": "Person",
"name": "Dawen Niu",
"url": "https://questionsmedicales.fr/author/Dawen%20Niu",
"affiliation": {
"@type": "Organization",
"name": "Department of Emergency, State Key Laboratory of Biotherapy, West China Hospital, and School of Chemical Engineering, Sichuan University, No. 17 Renmin Nan Road, Chengdu, 610041, China."
}
},
{
"@type": "Person",
"name": "Liang Yang",
"url": "https://questionsmedicales.fr/author/Liang%20Yang",
"affiliation": {
"@type": "Organization",
"name": "Department of Chemistry, University of Copenhagen, Universitetsparken 5, 2100 Copenhagen Ø, Denmark."
}
},
{
"@type": "Person",
"name": "Boon Chong Lee",
"url": "https://questionsmedicales.fr/author/Boon%20Chong%20Lee",
"affiliation": {
"@type": "Organization",
"name": "Department of Chemistry, National University of Singapore, 4 Science Drive 2, Singapore, 117544, Republic of Singapore."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Programmed cell death-1 blockade therapy in melanoma: Resistance mechanisms and combination strategies.",
"datePublished": "2023-01-24",
"url": "https://questionsmedicales.fr/article/36645031",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/exd.14750"
}
},
{
"@type": "ScholarlyArticle",
"name": "MicroRNAs Targeting Programmed Cell Death Protein 1 (PD-1) Promote Natural Killer Cell Exhaustion in Rheumatoid Arthritis.",
"datePublished": "2022-12-24",
"url": "https://questionsmedicales.fr/article/36640056",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.18502/ijaai.v21i6.11524"
}
},
{
"@type": "ScholarlyArticle",
"name": "Differential expression of programmed death 1 (PD-1) on various immune cells and its role in human leprosy.",
"datePublished": "2023-04-21",
"url": "https://questionsmedicales.fr/article/37153623",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fimmu.2023.1138145"
}
},
{
"@type": "ScholarlyArticle",
"name": "A High Programmed Cell Death Protein 1 Hormone Receptor Score on Skin Biopsy is Associated with Sézary Syndrome Diagnosis: A Study of 91 Patients with Erythroderma.",
"datePublished": "2022-09-06",
"url": "https://questionsmedicales.fr/article/35758515",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.2340/actadv.v102.1062"
}
},
{
"@type": "ScholarlyArticle",
"name": "Functionalized biomimetic nanoparticles combining programmed death-1/programmed death-ligand 1 blockade with photothermal ablation for enhanced colorectal cancer immunotherapy.",
"datePublished": "2022-11-25",
"url": "https://questionsmedicales.fr/article/36442821",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.actbio.2022.11.043"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Métabolisme",
"item": "https://questionsmedicales.fr/mesh/D008660"
},
{
"@type": "ListItem",
"position": 3,
"name": "Métabolisme glucidique",
"item": "https://questionsmedicales.fr/mesh/D050260"
},
{
"@type": "ListItem",
"position": 4,
"name": "Glycosylation",
"item": "https://questionsmedicales.fr/mesh/D006031"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Glycosylation - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Glycosylation",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-09",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Glycosylation",
"description": "Comment diagnostiquer une anomalie de glycosylation ?\nQuels tests sanguins sont utilisés pour la glycosylation ?\nLes biopsies sont-elles utiles pour la glycosylation ?\nQuels symptômes indiquent une anomalie de glycosylation ?\nPeut-on utiliser l'imagerie pour diagnostiquer la glycosylation ?",
"url": "https://questionsmedicales.fr/mesh/D006031?mesh_terms=Programmed+Cell+Death+1+Receptor&page=3#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Glycosylation",
"description": "Quels sont les symptômes d'une glycosylation anormale ?\nLa fatigue est-elle un symptôme de glycosylation ?\nLes troubles digestifs sont-ils liés à la glycosylation ?\nY a-t-il des symptômes cutanés associés ?\nLes problèmes de croissance sont-ils fréquents ?",
"url": "https://questionsmedicales.fr/mesh/D006031?mesh_terms=Programmed+Cell+Death+1+Receptor&page=3#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Glycosylation",
"description": "Peut-on prévenir les anomalies de glycosylation ?\nLe dépistage génétique est-il recommandé ?\nLes vaccinations aident-elles à prévenir les complications ?\nY a-t-il des conseils diététiques préventifs ?\nLes consultations médicales régulières sont-elles importantes ?",
"url": "https://questionsmedicales.fr/mesh/D006031?mesh_terms=Programmed+Cell+Death+1+Receptor&page=3#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Glycosylation",
"description": "Quels traitements existent pour les anomalies de glycosylation ?\nLes enzymes de remplacement sont-elles efficaces ?\nLa diététique joue-t-elle un rôle dans le traitement ?\nLes médicaments immunosuppresseurs sont-ils utilisés ?\nY a-t-il des traitements expérimentaux disponibles ?",
"url": "https://questionsmedicales.fr/mesh/D006031?mesh_terms=Programmed+Cell+Death+1+Receptor&page=3#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Glycosylation",
"description": "Quelles sont les complications possibles de la glycosylation ?\nLes infections sont-elles fréquentes chez ces patients ?\nY a-t-il des risques de cancer associés ?\nLes troubles cardiovasculaires sont-ils liés ?\nLes complications psychologiques sont-elles possibles ?",
"url": "https://questionsmedicales.fr/mesh/D006031?mesh_terms=Programmed+Cell+Death+1+Receptor&page=3#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Glycosylation",
"description": "Quels sont les facteurs de risque pour les anomalies de glycosylation ?\nL'âge joue-t-il un rôle dans la glycosylation ?\nLes facteurs environnementaux influencent-ils la glycosylation ?\nLes maladies métaboliques augmentent-elles le risque ?\nLe sexe a-t-il un impact sur la glycosylation ?",
"url": "https://questionsmedicales.fr/mesh/D006031?mesh_terms=Programmed+Cell+Death+1+Receptor&page=3#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une anomalie de glycosylation ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests génétiques et des analyses de glycoprotéines sont utilisés."
}
},
{
"@type": "Question",
"name": "Quels tests sanguins sont utilisés pour la glycosylation ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests de glycoprotéines et les profils glycosylés sont courants."
}
},
{
"@type": "Question",
"name": "Les biopsies sont-elles utiles pour la glycosylation ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les biopsies tissulaires peuvent révéler des anomalies de glycosylation."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent une anomalie de glycosylation ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des retards de développement, des problèmes immunitaires et des anomalies neurologiques."
}
},
{
"@type": "Question",
"name": "Peut-on utiliser l'imagerie pour diagnostiquer la glycosylation ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'imagerie n'est pas spécifique, mais peut aider à évaluer des complications."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une glycosylation anormale ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des troubles neurologiques, des infections fréquentes et des anomalies physiques."
}
},
{
"@type": "Question",
"name": "La fatigue est-elle un symptôme de glycosylation ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la fatigue peut être un symptôme associé à des troubles de glycosylation."
}
},
{
"@type": "Question",
"name": "Les troubles digestifs sont-ils liés à la glycosylation ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains troubles digestifs peuvent être liés à des anomalies de glycosylation."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes cutanés associés ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des éruptions cutanées et des anomalies de la peau peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les problèmes de croissance sont-ils fréquents ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des retards de croissance peuvent être observés chez les patients affectés."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les anomalies de glycosylation ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention est difficile, mais un diagnostic précoce peut aider à gérer les symptômes."
}
},
{
"@type": "Question",
"name": "Le dépistage génétique est-il recommandé ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le dépistage génétique peut être utile pour les familles à risque."
}
},
{
"@type": "Question",
"name": "Les vaccinations aident-elles à prévenir les complications ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les vaccinations peuvent réduire le risque d'infections chez ces patients."
}
},
{
"@type": "Question",
"name": "Y a-t-il des conseils diététiques préventifs ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée peut soutenir la santé globale et le système immunitaire."
}
},
{
"@type": "Question",
"name": "Les consultations médicales régulières sont-elles importantes ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles permettent de surveiller l'évolution et d'ajuster les traitements."
}
},
{
"@type": "Question",
"name": "Quels traitements existent pour les anomalies de glycosylation ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent des thérapies de soutien et des interventions spécifiques selon les symptômes."
}
},
{
"@type": "Question",
"name": "Les enzymes de remplacement sont-elles efficaces ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent être efficaces pour certaines formes de maladies liées à la glycosylation."
}
},
{
"@type": "Question",
"name": "La diététique joue-t-elle un rôle dans le traitement ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des régimes spécifiques peuvent aider à gérer certains symptômes."
}
},
{
"@type": "Question",
"name": "Les médicaments immunosuppresseurs sont-ils utilisés ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent être prescrits pour traiter des complications immunitaires."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements expérimentaux disponibles ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des essais cliniques sont en cours pour de nouvelles thérapies ciblées."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications possibles de la glycosylation ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des troubles neurologiques, des infections et des problèmes de croissance."
}
},
{
"@type": "Question",
"name": "Les infections sont-elles fréquentes chez ces patients ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les patients peuvent être plus susceptibles aux infections en raison d'un système immunitaire affaibli."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques de cancer associés ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines anomalies de glycosylation peuvent augmenter le risque de cancers spécifiques."
}
},
{
"@type": "Question",
"name": "Les troubles cardiovasculaires sont-ils liés ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des troubles cardiovasculaires peuvent survenir chez certains patients."
}
},
{
"@type": "Question",
"name": "Les complications psychologiques sont-elles possibles ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des complications psychologiques comme l'anxiété peuvent être observées."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour les anomalies de glycosylation ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antécédents familiaux et certaines mutations génétiques sont des facteurs de risque."
}
},
{
"@type": "Question",
"name": "L'âge joue-t-il un rôle dans la glycosylation ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines anomalies peuvent se manifester plus tôt dans l'enfance, mais d'autres plus tard."
}
},
{
"@type": "Question",
"name": "Les facteurs environnementaux influencent-ils la glycosylation ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des facteurs environnementaux peuvent interagir avec des prédispositions génétiques."
}
},
{
"@type": "Question",
"name": "Les maladies métaboliques augmentent-elles le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines maladies métaboliques peuvent être associées à des anomalies de glycosylation."
}
},
{
"@type": "Question",
"name": "Le sexe a-t-il un impact sur la glycosylation ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines anomalies peuvent avoir des manifestations différentes selon le sexe."
}
}
]
}
]
}
Melanoma is a highly aggressive tumor derived from melanocytes. In recent years, the incidence and mortality of melanoma have gradually increased, seriously threatening human health. Classic treatment...
Natural killer (NK) cells play a role in the pathogenesis of rheumatoid arthritis (RA). Upregulated levels of programmed cell death protein 1 (PD-1) is a sign of exhausted NK cells that could be regul...
Leprosy is a chronic bacterial disease caused by...
Erythroderma is challenging to diagnose. The aim of this single-centre retrospective study was to identify factors that can be used to improve the diagnosis of erythroderma. Among 91 patients with ery...
Immune checkpoint blockade therapy targeting programmed death-1 (PD-1) or its major ligand programmed death-ligand 1 (PD-L1) has achieved remarkable success in the treatment of several tumors, includi...
The immune system uses various immune checkpoint axes to adjust responses, support homeostasis, and deter self-reactivity and autoimmunity. Nevertheless, non-small-cell lung carcinoma (NSCLC) can use ...
Pembrolizumab or nivolumab plus chemotherapy was approved as a first-line treatment for high programmed cell death ligand 1 (PD-L1)-expressing esophageal squamous cell carcinoma (ESCC) by the European...
Post hoc analysis of the Chinese JUPITER-06 study focusing on efficacy stratified by PD-L1 tumor proportion score (TPS; using JS311 antibody) was conducted. Electronic databases were searched to ident...
The post hoc analysis of JUPITER-06 showed more prominent clinical benefit with PD-1 antibody plus chemotherapy than with chemotherapy alone in both the high and low PD-L1-expressing subgroups. Five r...
This study provided novel evidence supporting the superiority of PD-1 antibody plus chemotherapy to chemotherapy alone in patients with advanced ESCC with low PD-L1 expression. Further studies of pred...
Major depression (MD) may be associated with inflammation and immunity. PD-1 (programmed death-1), PD-L1 (programmed death-ligand 1) and PD-L2 (programmed death-ligand 2) are among the inhibitory immu...
During a period of 2 years, patients with MD and healthy controls were recruited from a medical centre in this study. The diagnosis of MD was established according to the DSM-5 criteria. The severity ...
A total of 54 patients with MD and 38 healthy controls were recruited. According to the analyses, there is a significantly higher PD-L2 level in MD than in healthy controls and lower PD-1 level after ...
It was found that PD-1 pathway might play an important role in MD. We need a large sample to prove these results in the future....
Tumor-infiltrating lymphocytes are detectable in up to 75% of triple-negative breast cancer. The composition of these infiltrates may influence prognosis and is not known regarding regulatory or effec...
This was a retrospective observational study. Clinical and pathological data from 38 triple-negative breast cancer patients treated with neoadjuvant chemotherapy at the University Hospital (HUCFF/UFRJ...
Statistically significant changes in stromal tumor-infiltrating lymphocyte categories were observed before and post-neoadjuvant chemotherapy, with 32% of intermediate cases becoming high. The correlat...
In this study, we observed that chemotherapy significantly increases stromal tumor-infiltrating lymphocytes, CD8 T cells, as well as CD8/FoxP3 ratio. Most importantly, programmed cell death protein 1 ...
Melanoma is widely treated with programmed cell death-1 (PD-1) inhibitors. As part of their anti-tumor immunity effect, they increase the susceptibility to cutaneous immune-related adverse events (cIR...